Last reviewed · How we verify
0.1% bupivacaine
At a glance
| Generic name | 0.1% bupivacaine |
|---|---|
| Sponsor | University of Leeds |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- Thoracic Epidural Analgesia With Bilateral Erector Spinae Plane Block in Radical Cystectomy Surgery (NA)
- Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery (NA)
- Ultrasound-Guided vs. Conventional Scalp Block for Postoperative Analgesia in Pediatric Supratentorial Tumor Surgeries (PHASE3)
- Quadratus Lumborum Block vs Intrathecal Morphine for Post-Cesarean Analgesia (NA)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.1% bupivacaine CI brief — competitive landscape report
- 0.1% bupivacaine updates RSS · CI watch RSS
- University of Leeds portfolio CI